Press release
ATLAS Biolabs expands services in molecular genetics to high-throughput SNP-genotyping based on mass spectrometry
Berlin, July 23, 2010 – By introducing Sequenom’s MassARRAY® Analyzer* for use in DNA analysis, ATLAS Biolabs GmbH aims to expand its range of services in molecular genetics. Sequenom’s innovative MassARRAY® system comprises a high-throughput platform which utilizes matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for genotyping of single nucleotide polymorphisms (SNPs). The system can be used for validating potential biomarkers identified by next-generation sequencing, for fine mapping of genome-wide association study (GWAS) data and for applications that employ defined SNP panels. The exceptional flexibility of the system allows for the quick adoption of newly discovered biomarkers into novel or existing biomarker panels.Mass spectrometry requires only very small amounts of genomic DNA and delivers extremely precise quantitative results, thereby providing substantial benefits for the analysis of genetic material. With the direct detection method it is possible to find even low frequency mutations, which might otherwise go undetected. Moreover, genotyping can be carried out not only with fresh and frozen material, but also with formalin-fixed, paraffin-embedded (FFPE) tissue samples. Since DNA purified from FFPE material is usually highly degraded and available only in small quantities, the molecular analysis of these samples is limited when using conventional methods.
„We are excited about the MassARRAY® system, which will help us to offer a valuable service to our customers. The system is an ideal complement to our range of services,“ said Professor Peter Nürnberg, Chief Executive Officer of ATLAS Biolabs. For example, MALDI-TOF MS is extremely valuable in SNP genotyping following GWAS, a field in which ATLAS Biolabs is one of the leading service providers in Europe, due to its proven experience with the whole-genome SNP chip technologies from Affymetrix and Illumina. In addition, by combining the MassARRAY® system with Sequenom’s OncoCarta™ panel**, ATLAS Biolabs is now able to rapidly monitor oncogene mutations in somatic cells.
“OncoCarta™ is currently the only panel for rare somatic mutation profiling that offers rapid parallel analysis of 238 mutations in 19 common oncogenes,” said Michael Monko, Senior Vice President, Sales & Marketing at Sequenom. “We look forward to close cooperation with ATLAS Biolabs to ensure that even more researchers in Europe have access to these innovative technologies, regardless of whether they are working in basic or clinical research or in drug development.“
The MassARRAY® System for SNP Genotyping
The MassARRAY® platform with the iPLEX® Gold genotyping assay** is a complete genotyping solution for the validation and fine mapping of SNPs and somatic mutations. The system includes software that can automatically design primers for multiplexed assays. In a subsequent reaction, primers are extended to detect sequence differences at the single nucleotide level. Following extension, products are spotted onto chip arrays, which are then placed in the MALDI-TOF mass spectrometer. A 384-position array is typically processed in 45-60 minutes. The results are automatically loaded into a database that allows convenient data analysis. Genotyping reactions can be multiplexed with up to 40 SNPs in each individual reaction, resulting in throughput levels of up to 150,000 genotypes per instrument per day.
*The MassARRAY Analyzer meets the safety requirements of the EMC Directive. For Research Use Only. Not for use in diagnostic procedures.
**For Research Use Only. Not for use in diagnostic procedures.
ATLAS Biolabs GmbH
ATLAS Biolabs GmbH is a leading provider of complex analyses in molecular genetics, including microarray-based genomic services, targeted sequence capture and next-generation sequencing in Europe. The company has access to the DNA chip platforms of all leading companies in this field (Affymetrix, Agilent,Illumina, and NimbleGen) and is a Certified Affymetrix, Agilent and NimbleGen Service Provider. The German company was founded in 2006. Customers of ATLAS Biolabs include academic institutions, pharmaceutical and biotechnological enterprises as well as clinicians and registered doctors in and outside of Germany. For more information please access www.atlas-biolabs.de.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a website at www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom website to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
ATLAS Biolabs GmbH
Friedrichstraße 147 | 10117 Berlin, Germany
Headquarter: Cologne, Germany
Chief Executive Officer: Prof. Dr. Peter Nürnberg
Press contact:
Mugele Kommunikation
Dr. Katrin Mugele
Phone: + 49 30 7816869
Fax: + 49 3212 7816869
E-mail: press@mugele-kommunikation.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ATLAS Biolabs expands services in molecular genetics to high-throughput SNP-genotyping based on mass spectrometry here
News-ID: 139251 • Views: …
More Releases from ATLAS Biolabs GmbH
ATLAS Biolabs expands its service portfolio to include the Agilent Expression Pr …
Berlin, Germany, August 20, 2008. ATLAS Biolabs GmbH has expanded its biochip-based services to include the Agilent technology platform. Thus, ATLAS Biolabs GmbH now also offers a third of the world’s three leading microarray technologies, in addition to Affymetrix and Illumina. Agilent’s chip technology is characterized by multiplex formats, high accuracy and reproducibility, as well as a high measure of flexibility. Production of customized chips thus becomes cheaper and faster.…
More Releases for Sequenom
Nucleic Acid Testing Market Is Booming Worldwide with Illumina, Sequenom, Tecan …
The "Global Nucleic Acid Testing" intelligence report, just published by USD Analytics, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Global Nucleic Acid Testing provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures…
Global SNP Genotyping and Analysis Market Size, Share, Forecast 2021 - 2030 | Ke …
The Global SNP Genotyping And Analysis Market Size is expected to reach USD 69,172 Million by 2030, at a CAGR of 22% during the forecast period 2021 to 2030.
Request To Download Free Sample copy of the report @ https://www.sphericalinsights.com/request-sample/1285
Our analysts are monitoring the situation globally to help you understand how COVID-19 will affect the SNP Genotyping and Analysis Market
The SNP Genotyping and Analysis global market research studies offer an in-depth…
Prenatal Diagnostics Market 2022 Segments Analysis by Top Key Players :Hologic, …
A recent market research report added to repository of MR Accuracy Reports is an in-depth analysis of global Prenatal Diagnostics. On the basis of historic growth analysis and current scenario of Prenatal Diagnostics place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent tools that…
cDNA And oDNA Microchips Market Insights by 2021| Sequenom, Inc., GE Healthcare
“Los Angeles, United States, Sept 2021,- QY Research has recently published a new report, titled Global and United States cDNA And oDNA Microchips Market Size, Status and Forecast 2021-2027 The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the cDNA And oDNA Microchips market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair…
SNP Genotyping Market Size 2019-2025 | Company Profiles by Sequenom, Inc., Dougl …
Single Nucleotide Polymorphisms also known as SNP genotypes are essentially a genetic variation detected in living organisms, adequately used to perceive uniqueness of DNA building blocks such as nucleotide. These SNPs are most commonly used to identify disease rendering genes and thus SNPs find ample usability as robust biological markers.
Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/1301
In most cases, SNPs are mainly inert with no palpable bearing on organism anatomical…
Prenatal Diagnostics Market 2019: Top Companies Analysis (Hologic, Sequenom, Per …
Prenatal Diagnostics Market Research Report till 2025 covers a detailed analysis of Prenatal Diagnostics Industry trends, top manufacturers, global opportunities, demand factors, distributor’s data and developments plans. In depth analysis comprising key market manufacturers, supply data and industry expert opinions.
Get Sample Copy of This Report at https://www.orianresearch.com/request-sample/770130
Development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and…
